Fauvel Charles, Dillinger Jean-Guillaume, Bochaton Thomas, Levasseur Thomas, El Ouahidi Amine, Zakine Cyril, El Hadad Antony, Mansencal Nicolas, Noirclerc Nathalie, Goralski Marc, Thuaire Christophe, Mewton Nathan, Schurtz Guillaume, Lim Pascal, Pommier Thibaut, Lemarchand Léo, Laissac Quentin, Lamblin Nicolas, Boukertouta Tanissia, Logeart Damien, Cohen-Solal Alain, Henry Patrick, Pezel Théo
Department of Cardiology, Normandie Univ, UNIROUEN, U1096, CHU Rouen, Rouen, France.
Department of Cardiology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
ESC Heart Fail. 2025 Aug;12(4):2736-2748. doi: 10.1002/ehf2.15118. Epub 2025 May 21.
The study aims to assess the in-hospital and 1 year incremental prognostic value of recent drug abuse use, detected by a systematic urinary screening, in a consecutive cohort of patients hospitalized for acute heart failure (AHF).
All patients admitted for AHF with a drug abuse screening using a urinary assay were included in this prospective multicentric study (39 French centres). The outcomes were (i) in-hospital major adverse cardiovascular events (MACEs) defined as all-cause death, resuscitated cardiac arrest or cardiogenic shock; and (ii) 1 year MACEs defined as cardiovascular death or hospitalization for AHF. Incremental prognostic value was assessed using the C-index, the global χ and likelihood-ratio (LR) test, the net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
In total, 458 patients with AHF were included (mean age 68 ± 14 years, 67% male, 79% of new heart failure onset). In-hospital and 1 year MACEs occurred, respectively, in 65 (14.2%) and 129 (28.2%) patients. Drug abuse detection was independently associated with in-hospital MACEs [model 1-known comorbidities: odds ratio (OR) = 4.46, 95% confidence interval (CI) (1.88-10.3), P < 0.001; model 2-clinical severity: OR = 3.64, 95% CI (1.56-8.26), P = 0.002], even after propensity-matched population analysis [OR = 3.34, 95% CI (1.32-8.70), P = 0.011], with a significant incremental prognostic value over and above traditional risk factors (C-statistic improvement 0.04 with LR test P < 0.001 for both models). Patients with drug abuse detection had worse 1 year survival: HR = 1.82, 95% CI (1.13-2.92), P = 0.012. Drug abuse detection was independently associated with 1 year MACEs after adjustment with traditional prognosticators [OR = 2.54, 95% CI (1.28-4.98), P = 0.008] and propensity-matched population analysis [OR = 2.77, 95% CI (1.98-5.21), P = 0.001], with an incremental prognostic value as well (C-statistic improvement 0.02, LR test P < 0.001, positive NRI and IDI).
Drug abuse use was independently associated with a higher occurrence of both in-hospital and 1 year MACEs with an incremental prognostic value. These results suggest a potential interest of a systematic illicit drug screening in these patients.
ClinicalTrials.gov Identifier: NCT05063097.
本研究旨在评估通过系统尿液筛查检测出的近期药物滥用情况,对因急性心力衰竭(AHF)住院的连续队列患者的院内及1年递增预后价值。
本前瞻性多中心研究(39个法国中心)纳入了所有因AHF入院且接受尿液检测进行药物滥用筛查的患者。结局指标为:(i)院内主要不良心血管事件(MACE),定义为全因死亡、复苏性心脏骤停或心源性休克;(ii)1年MACE,定义为心血管死亡或因AHF住院。使用C指数、全局χ和似然比(LR)检验、净重新分类改善(NRI)和综合判别改善(IDI)评估递增预后价值。
共纳入458例AHF患者(平均年龄68±14岁,67%为男性,79%为新发心力衰竭)。分别有65例(14.2%)和129例(28.2%)患者发生院内及1年MACE。药物滥用检测与院内MACE独立相关[模型1 - 已知合并症:比值比(OR)=4.46,95%置信区间(CI)(1.88 - 10.3),P<0.001;模型2 - 临床严重程度:OR = 3.64,95% CI(1.56 - 8.26),P = 0.002],即使在倾向匹配人群分析后也是如此[OR = 3.34,95% CI(1.32 - 8.70),P = 0.011],其递增预后价值显著高于传统危险因素(两个模型的C统计量改善均为0.04,LR检验P<0.001)。药物滥用检测呈阳性的患者1年生存率较差:风险比(HR)=1.82,95% CI(1.13 - 2.92),P = 0.012。在经传统预后因素调整后[OR = 2.54,95% CI(1.28 - 4.98),P = 0.008]以及倾向匹配人群分析后[OR = 2.77,95% CI(1.98 - 5.21),P = 0.001],药物滥用检测与1年MACE独立相关,且也具有递增预后价值(C统计量改善0.02,LR检验P<0.001,NRI和IDI为阳性)。
药物滥用与院内及1年MACE的较高发生率独立相关,且具有递增预后价值。这些结果表明对这些患者进行系统的非法药物筛查可能具有潜在意义。
ClinicalTrials.gov标识符:NCT05063097。